The Government of Ontario spending $3 million more than it needs to on biologic drugs every single week. Biosimilars are the solution, writes Biosimilars Canada President Jim Keon in his op-ed for QP Briefing.
Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
Effective October 1, 2021, adult patients who take NovoRapid insulin aspart will be required to switch to a biosimilar version by April 1, 2022. All new patient starts for insulin aspart will be covered for a biosimilar.
The Pharmacy Consulting Team at Telus Health looks at how Canada compares to Europe and the U.S. on biosimilars. Second in series.
The Pharmacy Consulting Team at Telus Health has published a good primer for private health insurers on biosimilars and the biosimilar landscape in Canada. First in series.
Effective August 1, adult patients covered by Alberta’s public drug plan who take Humalog insulin lispro will be required to switch to a biosimilar version by February 1, 2022. All new patient starts for insulin lispro will be covered for the biosimilar.
New Brunswick has expanded its biosimilar switching program. Patients who take Lovenox enoxaparin will need to switch to an enoxaparin biosimilar by Feb 28, 2022. New patient starts for enoxaparin will also be covered for a biosimilar.